Vigonvita executes 160,800-share buyback for HKD 12.67 million

Bulletin Express11-02

On 02 November 2026, Vigonvita Life Sciences Co., Ltd. repurchased 160,800 H-shares on the Hong Kong Stock Exchange, representing 0.10% of its issued share capital (excluding treasury shares) prior to the transaction. The shares were acquired at prices between HKD 75.40 and HKD 79.80, with a volume-weighted average cost of HKD 78.81 per share, bringing the total cash outlay to HKD 12.67 million.

Following the repurchase, outstanding shares (excluding treasury shares) declined to 166.60 million, while treasury shares rose to 0.30 million. The company’s total issued share count remained unchanged at 166.90 million, as the repurchased shares are being held in treasury rather than cancelled.

The transaction forms part of the share repurchase mandate approved on 30 June 2026, which authorises Vigonvita to buy back up to 6.67 million shares. Cumulative repurchases under this mandate now stand at 301,800 shares, equivalent to 0.45% of the issued share base at the time the mandate was granted. In accordance with exchange regulations, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 02 December 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment